<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" xml:lang="EN">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title>Emerging Infectious Diseases</journal-title>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18976587</article-id>
      <article-id pub-id-type="pmc">2630725</article-id>
      <article-id pub-id-type="publisher-id">07-1321</article-id>
      <article-id pub-id-type="doi">10.3201/eid1411.071321</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>Mycobacterium haemophilum</italic> Infection after Alemtuzumab Treatment</article-title>
        <alt-title alt-title-type="running-head"><italic>Mycobacterium haemophilum</italic> Infection after Alemtuzumab Treatment</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kamboj</surname>
            <given-names>Mini</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Louie</surname>
            <given-names>Eddie</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kiehn</surname>
            <given-names>Timothy</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Papanicolaou</surname>
            <given-names>Genovefa</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Glickman</surname>
            <given-names>Michael</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sepkowitz</surname>
            <given-names>Kent</given-names>
          </name>
        </contrib>
        <aff id="aff1">Memorial Sloan-Kettering Cancer Center, New York, New York, USA (M. Kamboj, T. Kiehn, G. Papanicolaou, M. Glickman, K. Sepkowitz)</aff>
        <aff id="aff2">New York University, New York (E. Louie)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Mini Kamboj, Department of Medicine, Memorial Sloan-Kettering Cancer Centers, 1275 York Ave, Box 9, New York, NY 10021, USA; email: <email xlink:href="kambojm@mskcc.org">kambojm@mskcc.org</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2008</year>
      </pub-date>
      <volume>14</volume>
      <issue>11</issue>
      <fpage>1821</fpage>
      <lpage>1823</lpage>
      <kwd-group kwd-group-type="author" xml:lang="EN">
        <title>Keywords: </title>
        <kwd>M. haemophilum</kwd>
        <kwd>infectious complications</kwd>
        <kwd>alemtuzumab</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor</bold>: The immunosuppressive agent alemtuzumab is a DNA-derived, humanized monoclonal antibody directed against the panlymphocyte, cell-surface antigen CD52 (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). The drug is approved for the treatment of refractory B-cell chronic lymphocytic leukemia (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>) and also has been used after stem cell (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>) and organ transplantations (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Alemtuzumab causes profound and prolonged lymphocyte depletion, which results in a variety of complications involving infections (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). However, mycobacteria have rarely been reported to cause infection after alemtuzumab treatment. We describe infections with <italic>Mycobacterium haemophilum</italic>, a fastidious nontuberculous mycobacterium, in 2 patients who experienced cutaneous lesions while they received alemtuzumab.</p>
    <sec sec-type="other1">
      <title>Patient 1</title>
      <p>A 65-year-old man with refractory chronic lymphocytic leukemia had been receiving treatment with alemtuzumab for 3 months. During a 5-week period beginning 15 weeks after the alemtuzumab therapy started, 20&#x2013;30 tender nodular-ulcerative lesions developed on the patient&#x2019;s extremities. Most of the lesions were distributed along a saphenous vein site (<xref ref-type="fig" rid="F1">Figure</xref>). Immediately before receiving alemtuzumab, he had been given rituximab for 3 months. A punch biopsy of the cutaneous lesion showed lymphogranulomatous inflammation in the dermis. Acid-fast stains of the skin punch biopsy specimen, as well as aspirated material from the lesions, demonstrated acid-fast bacilli. Cultures on Middlebrook 7H11 agar (Becton Dickinson and Company, Sparks, MD, USA) containing X-factor strips incubated at 30&#xB0;C showed growth of the acid-fast bacilli after 13 days. The isolate was subsequently identified as <italic>M. haemophilum</italic> by using conventional biochemical profiles and assessment of morphologic features, including an optimal growth temperature of 30&#xB0;C and a hemin requirement. The patient was treated with 4 drugs (rifampin, doxycycline, clarithromycin, ciprofloxacin), and he rapidly improved. Susceptibility testing, using broth MIC determinations described in Clinical and Laboratory Standards Institute publication M-24A (<ext-link ext-link-type="uri" xlink:href="http://www.clsi.org/source/orders/free/m24-aa.pdf">www.clsi.org/source/orders/free/m24-aa.pdf</ext-link>), indicated that the isolate was sensitive to clarithromycin, ciprofloxacin, clofazimine, and linezolid; intermediately sensitive to rifampin; but resistant to rifabutin, doxycycline, ethambutol, streptomycin, and amikacin. The antimicrobial drugs the patient was receiving were changed to only rifampin, clarithromycin, and ciprofloxacin. He completed a 6-month course of treatment course without recurrence of the lesions.</p>
      <fig id="F1" fig-type="figure" position="float">
        <label>Figure</label>
        <caption>
          <p>Nodular-ulcerative skin lesions on the left thigh caused by <italic>Mycobacterium haemophilum</italic> infection in a patient with chronic lymphocytic leukemia (patient 1) whose condition had been treated with alemtuzumab.</p>
        </caption>
        <graphic xlink:href="07-1321-F"/>
      </fig>
    </sec>
    <sec sec-type="other2">
      <title>Patient 2</title>
      <p>A 17-year-old woman with severe systemic lupus erythematosus and secondary myelodysplastic syndrome received an unrelated T-cell depleted bone marrow transplant. Her conditioning regimen included melphalan, thiotepa, fludarabine, and 2 doses of alemtuzumab. She initially did well posttransplant and was discharged from the hospital Approximately 3 months later, 40&#x2013;50 tender erythematous papular lesions developed on her extremities. A skin biopsy specimen showed mycobacterial panniculitis. Cultures from skin, blood, and bone marrow grew <italic>M. haemophilum</italic> after 18&#x2013;19 days&#x2019; incubation. She was successfully treated with rifampin, clarithromycin, and gatifloxacin; however, she died several months later from unrelated complications.</p>
      <p><italic>M. haemophilum</italic> was first described in 1978 when it was isolated from cutaneous lesions of a woman from Israel with Hodgkin disease (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). <italic>M. haemophilum</italic> most often causes joint, cutaneous, and pulmonary infections in immunocompromised patients (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>) and lymphadenitis in immunocompetent children (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). <italic>M. haemophilum</italic> is a fastidious organism that requires media supplemented with ferric ions in the form of hemin, hemoglobin, or ferric ammonium citrate, and incubation at 30&#xB0;C&#x2013;32&#xB0;C for several weeks. On the basis of our experience at Memorial Sloan-Kettering Cancer Center (23 cases of <italic>M. haemophilum</italic> infection observed from 1990 through 2000) (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>), the following specimens are routinely set up for culture: blood smear specimens that are positive for acid-fast bacilli, synovial or joint fluids, skin biopsy specimens, cutaneous lesions, ulcers, abscesses, lymph nodes, and lung biopsy specimens. Culture media include Middlebrook 7H11 agar plates with a hemin-containing paper strip (X-factor) placed on the agar surface that are then incubated at 30&#xB0;C for 6 weeks. Growth of the organism is usually detected within 2 to 3 weeks, and the isolates are usually susceptible in vitro to the quinolones, macrolides, and rifamycins and resistant to several drugs for tuberculosis, including ethambutol, isoniazid, and pyrazinamide (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>).</p>
      <p>Alemtuzumab has been associated with the development of infections caused by a variety of microorganisms. However, mycobacteria have infrequently been the reported cause. In a review of 547 organ transplant recipients who received alemtuzumab treatment, miliary tuberculosis developed in 1 recipient of a kidney transplant, and pulmonary infection with <italic>M. kansasii</italic> developed in 2 recipients of lung transplants (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). There is also a case report of systemic <italic>M. bovis</italic> infection developing in a patient with relapsing B chronic lymphocytic leukemia after administration of alemtuzumab (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>).</p>
      <p>Although we believe that alemtuzumab is responsible for the severe immunosuppression that predisposed these patients to <italic>M. haemophilum</italic> infection, other explanations are plausible. For example, patient 1 had received rituximab and cyclophosamide for 6 months. These drugs, in addition to his underlying disease of chromic lymphocytic leukemia, may have predisposed him to <italic>M. haemophilum</italic> infection. However, his lesions did not appear until he received alemtuzumab. In patient 2, the immunosuppression associated with his transplant may have predisposed the patient to <italic>M. haemophilum</italic> infection.</p>
      <p>This report identifies <italic>M. haemophilum</italic> as an opportunistic pathogen in patients who have received alemtuzumab. We recommend that all patients who have received at least 1 dose of alemtuzumab, and who have undiagnosed tender skin lesions located over the extremities, be evaluated by using appropriate techniques to isolate <italic>M. haemophilum.</italic> Communication with microbiology laboratory staff concerning appropriate methods for detection of the organism is crucial.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Kamboj M, Louie E, Kiehn T, Papanicolaou G, Glickman M, Sepkowitz K. <italic>Mycobacterium haemophilum</italic> infection after alemtuzumab treatment. Emerg Infect Dis [serial on the Internet]. 2008 Nov [<italic>date cited</italic>]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/14/11/1821.htm">http://www.cdc.gov/EID/content/14/11/1821.htm</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <citation citation-type="journal"><string-name><surname>Ferrajoli</surname> <given-names>A</given-names></string-name>, <string-name><surname>O&#x2019;Brien</surname> <given-names>S</given-names></string-name>, <string-name><surname>Keating</surname> <given-names>MJ</given-names></string-name> <article-title>Alemtuzumab: a novel monoclonal antibody.</article-title><source>Expert Opin Biol Ther</source> <year>2001</year>;<volume>1</volume>:<fpage>1059</fpage>&#x2013;<lpage>65</lpage> <pub-id pub-id-type="doi">10.1517/14712598.1.6.1059</pub-id><pub-id pub-id-type="pmid">11728236</pub-id></citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <citation citation-type="journal"><string-name><surname>Keating</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Flinn</surname> <given-names>I</given-names></string-name>, <string-name><surname>Jain</surname> <given-names>V</given-names></string-name>, <string-name><surname>Binet</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Hillmen</surname> <given-names>P</given-names></string-name>, <string-name><surname>Byrd</surname> <given-names>J</given-names></string-name>, <etal/><article-title>Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.</article-title><source>Blood</source> <year>2002</year>;<volume>99</volume>:<fpage>3554</fpage>&#x2013;<lpage>61</lpage> <pub-id pub-id-type="doi">10.1182/blood.V99.10.3554</pub-id><pub-id pub-id-type="pmid">11986207</pub-id></citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <citation citation-type="journal"><string-name><surname>Ho</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Pagliuca</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kenyon</surname> <given-names>M</given-names></string-name>, <string-name><surname>Parker</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Mijovic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Devereux</surname> <given-names>S</given-names></string-name>, <etal/><article-title>Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.</article-title><source>Blood</source> <year>2004</year>;<volume>104</volume>:<fpage>1616</fpage>&#x2013;<lpage>23</lpage> <pub-id pub-id-type="doi">10.1182/blood-2003-12-4207</pub-id><pub-id pub-id-type="pmid">15059843</pub-id></citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <citation citation-type="journal"><string-name><surname>Shapiro</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ellis</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Moritz</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Basu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Vats</surname> <given-names>AN</given-names></string-name>, <etal/><article-title>Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.</article-title><source>J Pediatr</source> <year>2006</year>;<volume>148</volume>:<fpage>813</fpage>&#x2013;<lpage>8</lpage> <pub-id pub-id-type="doi">10.1016/j.jpeds.2006.01.008</pub-id><pub-id pub-id-type="pmid">16769394</pub-id></citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <citation citation-type="journal"><string-name><surname>Peleg</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Husain</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kwak</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Silveira</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Ndirangu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tran</surname> <given-names>J</given-names></string-name>, <etal/><article-title>Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.</article-title><source>Clin Infect Dis</source> <year>2007</year>;<volume>44</volume>:<fpage>204</fpage>&#x2013;<lpage>12</lpage> <pub-id pub-id-type="doi">10.1086/510388</pub-id><pub-id pub-id-type="pmid">17173218</pub-id></citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <citation citation-type="journal"><string-name><surname>Sompolinsky</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lagziel</surname> <given-names>A</given-names></string-name>, <string-name><surname>Naveh</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yankilevitz</surname> <given-names>T</given-names></string-name> <article-title><italic>Mycobacterium haemophilum</italic> sp. nov., a new pathogen of humans.</article-title><source>Int J Syst Bacteriol</source> <year>1978</year>;<volume>28</volume>:<fpage>67</fpage>&#x2013;<lpage>75</lpage></citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <citation citation-type="journal"><string-name><surname>Saubolle</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Kiehn</surname> <given-names>TE</given-names></string-name>, <string-name><surname>White</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Rudinsky</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Armstrong</surname> <given-names>D</given-names></string-name> <article-title><italic>Mycobacterium haemophilum</italic>: microbiology and expanding clinical and geographic spectra of disease in humans.</article-title><source>Clin Microbiol Rev</source> <year>1996</year>;<volume>9</volume>:<fpage>435</fpage>&#x2013;<lpage>47</lpage><pub-id pub-id-type="pmid">8894345</pub-id></citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <citation citation-type="journal"><string-name><surname>Bruijnesteijn van Coppenraet</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Kuijper</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Lindeboom</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Prins</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Class</surname> <given-names>EC</given-names></string-name> <article-title><italic>Mycobacterium haemophilum</italic> and lymphadenitis in children.</article-title><source>Emerg Infect Dis</source> <year>2005</year>;<volume>11</volume>:<fpage>62</fpage>&#x2013;<lpage>8</lpage><pub-id pub-id-type="pmid">15705324</pub-id></citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <citation citation-type="journal"><string-name><surname>Shah</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Sebti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kiehn</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Massarella</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Sepkowitz</surname> <given-names>KA</given-names></string-name> <article-title><italic>Mycobacterium haemophilum</italic> in immunocompromised patients.</article-title><source>Clin Infect Dis</source> <year>2001</year>;<volume>33</volume>:<fpage>330</fpage>&#x2013;<lpage>7</lpage> <pub-id pub-id-type="doi">10.1086/321894</pub-id><pub-id pub-id-type="pmid">11438898</pub-id></citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <citation citation-type="journal"><string-name><surname>Abad</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gyan</surname> <given-names>E</given-names></string-name>, <string-name><surname>Moachon</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bouscary</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sicard</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dreyfus</surname> <given-names>F</given-names></string-name>, <etal/><article-title>Tuberculosis due to <italic>Mycobacterium bovis</italic> after alemtuzumab administration.</article-title><source>Clin Infect Dis</source> <year>2003</year>;<volume>37</volume>:<fpage>e27</fpage>&#x2013;<lpage>8</lpage> <pub-id pub-id-type="doi">10.1086/375690</pub-id><pub-id pub-id-type="pmid">12856232</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
